Benjamine Liu

Benjamine Liu is the co-founder and CEO of Formation Bio, an AI-native pharmaceutical company in New York that licenses and develops its own drug pipeline. A Rhodes Scholar with a DPhil from Oxford, he started the company (originally TrialSpark) in 2016 after concluding during his graduate work that clinical trials, not discovery, were the real bottleneck slowing new treatments from reaching patients. Formation Bio has raised over $610 million, including a $372 million Series D led by a16z with backing from Sanofi.